|
MORRISVILLE, N.C. (AP) -- BioDelivery Sciences International Inc. said Monday it exercised an option to buy the U.S. rights to a drug-delivery technology from QLT Inc.'s U.S. subsidiary for $7 million. At the same time, BioDelivery Sciences entered into a $30 million license and supply agreement with Meda AB to commercialize a Fentanyl product using the technology in North America. That deal is subject to antitrust review. Under the terms of the rights deal, BioDelivery Sciences will pay QLT USA Inc. $3 million upfront for the rights to the BEMA dissolvable disk delivery system, plus two later payments of $2 million apiece based on certain performance milestones. QLT USA is a division of Vancouver-based QLT. BioDelivery Sciences already owns the non-U.S. rights to the BEMA technology, according to the company's Web site. The system is made up of a dissolvable dime-sized polymer disc that patients place inside their cheek. BioDelivery Sciences paid for the initial payment to QLT using a short-term bank note, which it plans to repay with part of its anticipated payment from Meda in October. Shares of BioDelivery Sciences fell 4 cents to $3.95.
|